The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Interesting the shift to 'mild to moderate' from the 'moderate to severe' originally planned. That and the 'take home' aspect presumably will open it to a much bigger market ultimately if the trials are successful.
No I’m not GC or Hannah or anyone else in Tils.
Just really interested in the products and it’s certainly been a rollercoaster.
No joking, good luck with your investing, we all deserve to win.
As you have only ever posted positive fluff on Tils in all of your 600 posts
Cloudy it's interesting that you opened an LSE account in June 2014, incidentally the same month and year that Tils got going.
Are you actually GC?
Well bye bye then see you when they are well underway!
I did. There are no trials in progress.
So no reason to invest.
Prefer to invest in a company that is at least trying to get its drugs approved.
Read the presentations!
What are the near term catalysts?
Hind sight is a wonderful thing !
Start looking forward and the opportunities ahead and stop trying to influence peoples decisions.
You sold you lost , now will you buy in cheaper than you sold?
If people had listened to me a year or so ago when I first started raising concerns they might have saved a lot of money
Why are you here Sangi if you don’t like it that much!
You seem to be a paid deramper!
Where's the data for peer review and independent analysis Hannah?
4D and other companies are 80% down. I just invested in Evelo 75% down and so is Seres.
They are all due to release data and results from trials, which is the only thing that will lift a biotech in a bear market.
Horses mouth.
“We are very pleased with the tolerability of both oral and nasally administered Foralumab” added Dr. Tanuja Chitnis, Professor of Neurology at Harvard Medical School, and study Principal Investigator (PI).
Ok Hannah
Will happen when the Brazilians give the go ahead.
4D is battered. But I am still happy holding and buying.
The best thing I did was get out here when it was in the 80s.
What is it? 30p now in old money and still no trials.
What is a biotech without a trial?
Trials or no trials, this hasn’t changed the outcome for many biotechs. Over 12 months many are 60-80% down.
Why would anyone invest until the trend changes. Hindsight trading is easy. Unfortunately I invested here to early. Start to build 4d now though.
BB
That's a press release. Where is the trial registered or published?
How long was dosing for? It doesn't say
On numerous occasions that Covid restricted trials.
Which. I can well believe.
And this amended 5 day take home experiment will be a lot more feasible to do.
Quite a few people now have had foralumab for one reason or another and no one has had extreme adverse avents when taken orally or nasally.
So I am pleased if this goes ahead and the MS trial goes further as it was the FDA that only let them try it slowly at first.
I’m happy, Oh you lucky people we are at the beginning!
Why does the great and all-knowing Sangi say there is no safety data on oral Foralumab? https://www.businesswire.com/news/home/20200109005415/en/Tiziana-Reports-Phase-1-Clinical-Data-Demonstrating-Oral-Treatment-with-Foralumab-a-Fully-Human-Anti-CD3-Monoclonal-Antibody-is-Well-tolerated-in-Healthy-Volunteers
It was June last year they said they had signed a contract to set up P2
Still nothing
In all the time they have been going the only trial for Foralumab where data has been published publicly was the Brazil Covid trial.
They are not obliged to publish but doing so is helpful for investors and other scientists and researchers.
2 other trials for safety data with murine anti CD3 were over 30 days.
There are over 700 biotechs on Nasdaq most of which are running trials. Why would anyone invest here?
SJ1
The filing states:
This amendment would allow for the investigation of a broader patient population as well as a shorter dosing period. Previously, Tiziana had submitted an IND to conduct a Phase 1b study in moderate-to-severe active Crohn’s Disease patients to evaluate safety of enteric-coated foralumab capsules administered orally once daily for 14 days as an inpatient study in the hospital or CRU with safety monitoring, for which the FDA issued a ‘Study May Proceed letter’.
‘Study may proceed later’ - Is this why they’ve amended the original. Will they carryout the original IND afterwards?
BB
A trial was set up and IND registered. The record has not been amended to reflect the new trial design.
The trial protocol including dose escalation has been ripped up and they are now going to dose with 5mg
One excuse after another to explain why 0 trials are running.
And no the 1 patient in the MS does not count as that will just produce an anecdote rather than any significant data.
Why do you think other companies do trials in multiple participants? I guess they must all be doing it wrong!